Skip to main content

Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: results of a multicenter randomized placebo-controlled clinical trial

Abstract

Background

Surgical site infections (SSIs) are common complications after colorectal surgery. Oral non-absorbable antibiotic prophylaxis (OAP) can be administered preoperatively to reduce the risk of SSIs. Its efficacy without simultaneous mechanical cleaning is unknown.

Methods

The Precaution trial was a double-blind, placebo-controlled randomized clinical trial conducted in six Dutch hospitals. Adult patients who underwent elective colorectal surgery were randomized to receive either a three-day course of preoperative OAP with tobramycin and colistin or placebo. The primary composite endpoint was the incidence of deep SSI or mortality within 30 days after surgery. Secondary endpoints included both infectious and non-infectious complications at 30 days and six months after surgery.

Results

The study was prematurely ended due to the loss of clinical equipoise. At that time, 39 patients had been randomized to active OAP and 39 to placebo, which reflected 8.1% of the initially pursued sample size. Nine (11.5%) patients developed the primary outcome, of whom four had been randomized to OAP (4/39; 10.3%) and five to placebo (5/39; 12.8%). This corresponds to a risk ratio in the intention-to-treat analysis of 0.80 (95% confidence interval (CI) 0.23–2.78). In the per-protocol analysis, the relative risk was 0.64 (95% CI 0.12–3.46).

Conclusions

Observational data emerging during the study provided new evidence for the effectiveness of OAP that changed both the clinical and medical ethical landscape for infection prevention in colorectal surgery. We therefore consider it unethical to continue randomizing patients to placebo. We recommend the implementation of OAP in clinical practice and continuing monitoring of infection rates and antibiotic susceptibilities.

Trial registration

The PreCaution trial is registered in the Netherlands Trial Register under NL5932 (previously: NTR6113) as well as in the EudraCT register under 2015–005736-17.

Background

Surgical site infections (SSIs) are among the most common healthcare-associated infections and affect approximately 10 in every 100 patients who undergo colorectal surgery [1, 2]. SSIs were associated with a substantial increase in morbidity [3] and mortality [4, 5], prolongation of hospital stays [6, 7] and higher health-care costs [8,9,10,11]. Despite the widespread adoption of infection prevention measures aimed at reducing SSIs, the risk remains high, which underlines the importance of exploring additional precautions [2]. In the past, preoperative oral non-absorbable antibiotics were applied as an infection control strategy for colorectal surgery. Because it was assumed that local antibiotics could only be effective in an “empty” colon, simultaneous cleansing was applied with osmotic fluids [12]. Routine use of this cleansing, also referred to as mechanical bowel preparation (MBP), has recently become controversial due to lack of evidence for advantageous effects. At the same time, there are certain disadvantages, like the risk of dehydration, anastomotic leakage, or patient discomfort [13, 14]. At the same time, the oral antibiotics, which were often considered to be part of the MBP bundle, were abandoned even though their efficacy without simultaneous MBP is unclear. Our study aimed to determine the efficacy of preoperative oral non-absorbable antibiotic prophylaxis (OAP) without the routine administration of MBP on the risk of SSIs after elective colorectal surgery.

Methods

An in-depth description of the rationale and methods was published previously [15]. The trial is registered in the Netherlands Trial Register under NL5932.

Trial design, participants and randomization

The study was designed as a double-blind placebo-controlled randomized trial and was conducted from April 2017 through August 2018 in six Dutch hospitals. (Supplementary Table 1) Patients who were scheduled for colorectal surgery and who had no absolute contraindication for the study medication [15] were eligible to participate. Written informed consent was obtained from all participants. Eligible patients were randomly assigned in a 1:1 ratio to active OAP or placebo. The randomization was performed by an independent pharmacist, using a permuted block design with varying block sizes and stratified per study center. The study’s medication was packed in identical containers that were sequentially numbered with unique numbers. The list that linked these unique numbers to the treatment allocation was securely kept at the coordinating pharmacy (Amphia Hospital, Breda, the Netherlands). Everyone who was involved in the study was blinded to the allocation until the end of the study.

Intervention

OAP was a solution of tobramycin (16 mg/mL) and colistin sulphate (20 mg/mL) that was taken four times daily during the three days before surgery. Each dose was 5 mL. Placebo had an identical color, smell, and taste. The study medication was packed in bottles (100 mL) and distributed with 5 mL syringes. The bottles were returned to the hospital after the intervention period and were weighted to estimate treatment compliance. All patients received perioperative intravenous antibiotic prophylaxis according to the national guidelines [16].

Outcomes and safety reporting

Definitions of all outcomes are summarized in Fig. 1 and were described in more detail in the trial protocol [15]. The primary outcome was deep SSI and/or mortality in the 30 days after surgery. The CDC criteria were used to diagnose SSIs [17]. Rectal carriage of HRE comprised extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E), and (non-intrinsic) carbapenem-resistant, tobramycin-resistant and (non-intrinsic) colistin-resistant Gram-negative Enterobacteriaceae. HRE carriage was assessed by selective screening of rectal swabs that were obtained at inclusion and 30 days after surgery. EUCAST clinical breakpoints were used to interpret MICs [18]. Cultures with a transport time of more than 72 h were excluded from analyses as reliability and quality could not be guaranteed. Quality of life was assessed with the Rand-36 questionnaire [19]. This standardized questionnaire contains eleven questions to assess the quality of life on nine different scales. The scale scores range from 0 to 100%. Adverse events (AE) related to the study medication were self-reported in a medication diary. Other protocol related AE, Serious Adverse Events (SAE), Serious Adverse Reactions (SARs), and Suspected Unexpected Serious Adverse Reactions (SUSARs) were reported according to Good Clinical Practice guidelines [20].

Fig. 1
figure1

Definitions of primary and secondary endpoints. SSIs were diagnosed with the CDC criteria [17]. CDC, Centers for Disease Control and Infection Prevention; ESBL-E, extended spectrum beta-lactamase producing Enterobacteriaceae; ICU, intensive care unit; SSI, surgical site infection

Study procedures and data collection

An overview of the study procedures is provided in Supplementary Table 2. Demographic patient data, surgery characteristics, and data on the primary and secondary endpoints were collected from the medical records. Whole-genome sequencing was performed of all resistant isolates to identify the presence of acquired resistance genes.

Statistical analysis

Sample size calculation

We assumed a 14.4% baseline incidence and a 40% relative reduction in the primary endpoint to calculate the sample size. This was based on results from a before-after study that was performed in a Dutch teaching hospital where OAP was introduced as a standard of care before elective colorectal surgery [21]. With a one-sided alpha of 2.5%, power of 80%, and one interim analysis, the final sample size resulted in 966 patients.

Data analysis

Data were analyzed according to the intention-to-treat principle. We calculated crude risks for every outcome and a corresponding risk ratio (RR) and 95% confidence interval (CI) to compare the risks in the intervention arm with the placebo arm. A per-protocol analysis was performed in the 100% compliant population. Continuous outcomes were analyzed using Student’s t-test or Mann Whitney U-test, as appropriate. Quality of life after six months was corrected for the baseline scores by calculating the change (delta) in scores. Negative deltas reflect a worse perception of quality of life compared to baseline, whereas positive values reflect improvement. We evaluated whether our study population was a representative sample of the patient population by comparing average baseline characteristics with surveillance data from a Dutch hospital that did not participate in the study. Statistical analyses were performed using R version 3.3.2.

Results

Patient enrollment is shown in Fig. 2. The number of participants and the inclusion period per hospital are presented in Supplementary Table 3. The trial ended after 18 months when 78 participants (8.1% of the sample size) had been enrolled. All patients completed the intervention period. During the six-month follow-up period, one person was lost to follow-up and four discontinued active participation but gave consent to continue data collection from their medical records.

Fig. 2
figure2

CONSORT flowchart of enrolment of participants. Logistical issues were unexpected changes in the date of surgery that led to insufficient time to complete the three-day intervention period (n = 1) or missed appointments for the informed consent procedure due last-minute changes in the outpatient clinic schedule (n = 3)

The baseline characteristics of the participants are shown in Table 1. Thirty-nine patients were included in each treatment arm. The median age was 68 years, and 68% of patients were male. Colorectal malignancies were the indication for surgery in all except one of the patients (98.7%). Even though it was not part of routine care, MBP was applied in 3.8% of the patients. Based on the leftovers of study medication that were returned, we estimated that 57.7% of the patients took all twelve doses of study treatment.

Table 1 Baseline characteristics

The effect of OAP on primary and secondary outcomes is presented in Table 2. In total, nine (11.5%) patients developed outcome deep surgical site infection; all survived. Four received OAP (4/39; 10.3%) and five placebo (5/39; 12.8%). This corresponds to a risk ratio in the intention to treat analysis of 0.80 (95% CI [0.23–2.78]). There was no statistical difference between the treatment arms for any of the outcomes, except for a difference in the quality of life after six months that was improved compared to baseline on most scales in patients who had received OAP, and worsened in patients who had received placebo. In the per-protocol analysis, the risk ratio for the primary outcome was 0.64 (95% CI 0.12–3.46). The predictive power for the planned sample size given the observed results (that is, the probability of having a significant result at the end of the study, was for it to be completed, given the observed results in the 78 patients) was 67%. Due to insufficient power, we were unable to perform any of the preplanned subgroup analyses [15].

Table 2 Intention-to-treat analysis of OAP on the risk on primary and secondary outcomes

We collected 66 valid baseline rectal swabs and 62 valid follow-up rectal swabs (Table 3). There is no difference between the carriage of antibiotic-resistant micro-organisms between the two treatment arms at baseline or 30 days after surgery. In colistin-resistant isolates, no acquired colistin resistance genes were found. The carriage of tobramycin resistant species was approximately 40% both at baseline and 30 days after surgery, which was due to acquired tobramycin resistance genes in 9% of the cultures at baseline and 19.4% 30 days after surgery.

Table 3 Rectal carriage of (non-intrinsic) antibiotic resistant microorganisms

Of the eleven SSI that developed, three were confirmed with a microbiological culture, of which two were performed on abdominal pus collected during reoperation and one directly on the incision. (Supplementary Table 4). None of the pathogens cultured were resistant to tobramycin or colistin.

Adverse events during the intervention period are presented in Table 4. Out of the 65 (83.3%) patients who returned their medication diary, 56 (86.2%) patients took at least one dose of study medication. Of those, 24 (42.9%) did not report any side effects. The most adverse events were gastrointestinal side effects. Patients who received OAP more often reported diarrhea compared to those who received a placebo (51.9% versus 20.7%) as well as nausea (11.1% versus none). During the study, there was one SAE, which was a transient ischemic attack that occurred before the start of the intervention phase. No other adverse events related to either study medication or other study procedures were reported.

Table 4 Adverse events

To estimate whether our cohort was a representative sample of the patient population, we compared the baseline characteristics with a comparison cohort of 1597 patients. (Supplementary Table 5) Compared to the comparison cohort, the patients in the trial cohort were more often men, (67.9% versus 55.5%), had more colorectal malignancies (98.7% versus 74.5%), more minimally invasive procedures, but less abdominal surgery in the preceding year (3.8% versus 12.0%). The quality of life indicators, as shown in Table 2, all showed a more positive trend in the OAP group with a significant difference for social, physical, and emotional role functioning.

Discussion

Due to the premature termination of this multicenter, double-blind, placebo-controlled randomized clinical trial, we were unable to determine the efficacy of OAP in terms of the risk of SSI and other postoperative complications.

The use of oral antibiotic prophylaxis in colorectal surgery is a controversial topic. Several studies demonstrated a reduced risk of SSI when OAP was administered before surgery [23, 24]. However, the question of whether preoperative oral antibiotic prophylaxis is effective without MBP remains unanswered as all RCTs published to date combine OAP with MBP. The best available evidence on OAP efficacy is provided by a recent network meta-analysis that aimed to study the best strategy for bowel preparation. This study also emphasized the knowledge gap on OAP without MBP, as the absence of RCTs that included this strategy as a treatment arm forced the authors to estimate the efficacy of OAP based on indirect comparisons only. Though based on indirect comparisons, a significant reduction in organ/space SSIs was found with OAP only, compared to no preparation (OR 0.13 [95% CrI 0.02–0.55]). This strategy was superior to combining OAP with MBP.

Data on the effectiveness of OAP without simultaneous MBP is also provided by several retrospective observational studies that compared the different bowel preparation strategies. These studies reported conflicting results on effectiveness [25,26,27,28,29,30,31,32,33,34,35,36]. Potential confounding by indication and limited numbers of patients treated with only OAP hamper concluding on the effectiveness of OAP in the absence of MBP and exemplifies the need for well-controlled and adequately powered studies.

We consider the randomized design as a major strength of our study, which facilitated the unbiased assessment of the efficacy of OAP and its potential drug-related side effects. Although the quality of our design is high, selective participation could not be prevented entirely. Unfortunately, not all potential participants were screened. Patients suffering from multiple or more severe comorbidities were not always considered for participation even though they were eligible. This might have had an impact on the generalizability of the study population. Also, multiple other studies were being conducted within this patient population, which competed with our inclusions. Baseline characteristics of our cohort showed potentially relevant differences with those from a historical cohort of patients undergoing colorectal surgery from a different hospital. There are indications that the patients that we included differed from the source population. For example, the percentage of patients with colorectal malignancy in our cohort was higher. A recently implemented national screening program for colorectal cancer led to the detection of malignancies in an earlier stage. In general, these patients are in a better clinical condition, and surgery is less radical, which lowers the risk of SSI.

Treatment with OAP was associated with a significant improvement in perception of quality of life at six months after surgery. At the same time, worsening was seen for patients treated with a placebo. In the absence of an effect of OAP on any of the clinical outcomes that could have been a possible explanation for this improvement, we suggest further investigation to study whether and how OAP might impact the quality of life.

Because of the small sample size, we were unable to study the safety of OAP thoroughly. However, several patients who received OAP reported mild gastrointestinal side effects and an unappealing taste. When OAP is considered for implementation in the future, patients should be informed about these potential side effects and the necessity of completing the entire three-day course of OAP despite these side effects. Another important safety concern is the risk of developing antibiotic resistance. We found the prevalence of colistin and tobramycin resistance at baseline to be 16.7 and 39.4%, respectively. The prevalence of carriage of tobramycin and colistin-resistant species did not increase in both treatment arms. We compared our findings with the results obtained with the implementation of selective decontamination of the digestive tract (SDD), a comparable antibiotic prophylaxis containing tobramycin, colistin, and nystatin that is used in several Dutch ICUs. In a post hoc analysis of two multicenter trials, it was shown that during SDD use, the prevalence of colistin resistance ranged from 1.7 to 2.8%, and of tobramycin resistance from 6.2 to 8.0%, respectively [37]. Other studies on SDD found a comparable prevalence [38,39,40]. The selective culture methods that we used in our study are known to have a higher sensitivity to detect antimicrobial-resistant Gram-negative bacteria [41], and may explain the higher prevalence observed compared to other studies. Due to the small number of patients, we were unable to exclude that OAP may increase the risk of developing antibiotic resistance.

Ethical considerations

At the time this trial was initiated, there was no consensus within the Dutch surgical community on whether OAP should be used before colorectal surgery and, as a result, it was not part of clinical care in the vast majority of hospitals. Because of the uncertainty about the efficacy of the intervention, there was clinical equipoise regarding the use of OAP [42]. The shift started when the findings of a single-center before-after study were published. This before-after study was performed in the same setting without routine MBP administration [21]. In contrast to previous observational studies, the risk of confounding by indication was minimized because OAP was implemented as the standard of care and prescribed to all patients who underwent elective colorectal surgery. After implementation, a 42% reduction was observed in the risk of SSI and mortality within 30 days after surgery (aRR 0.58 [95% CI 0.40–0.79)]. Due to the single-center aspect of the study and the risk of residual confounding, a well-controlled study was deemed necessary to confirm the treatment effect.

We faced multiple problems recruiting participants throughout the entire study period despite our efforts to improve the inclusion rate. The unexpectedly low recruitment rate was communicated with the participating hospitals. Supported by the effectiveness found in the observational study, several investigators considered awaiting the trial results unacceptable and decided to implement OAP to reduce SSI rates. We decided to end the trial prematurely, because the assumption of clinical equipoise regarding the administration of OAP was no longer valid, and the use of a placebo was no longer ethically justifiable.

To conclude, we could not evaluate the efficacy of OAP on SSI risk and other postoperative complications after colorectal surgery due to premature termination of this double-blind, placebo-controlled, randomized clinical trial. Due to the loss of clinical equipoise, we will no longer consider the use of placebo in clinical trials on the efficacy of OAP ethics. Considering the current evidence, we recommend the implementation of OAP in clinical practice and the continued monitoring of infection rates and antimicrobial resistance.

Availability of data and materials

The metadata file is available on the DataverseNL data repository https://dataverse.nl/dataset.xhtml?persistentId=hdl:10411/7BKGVB.

Abbreviations

ASA:

American Society of Anesthesiologists

BMI:

Body mass index

CI:

Confidence interval

DOT:

Days on therapy

DSMB:

Data safety and monitoring board

eCRF:

Electronic case report form

ESBL:

Extended-spectrum beta-lactamase

HRE:

Highly-resistant Enterobacteriaceae

IQR:

Interquartile range

GCP:

Good clinical practice

ICU:

Intensive care unit

MBP:

Mechanical bowel preparation

OAP:

Preoperative oral antibiotic prophylaxis

RCT:

Randomized controlled trial

RR:

Risk ratio

SAE:

Serious adverse event

SAR:

Serious adverse reaction

SDD:

Selective decontamination of the digestive tract

SSI:

Surgical site infection

SUSAR:

Suspected unexpected serious adverse reaction

References

  1. 1.

    PREZIES. Referentiecijfers POWI 2012–2016.; 2017. https://www.rivm.nl/documenten/referentiecijfers-powi-2012-2016. Accesed 15 Jan 2019.

  2. 2.

    ECDC. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Surgical Site Infections. Stockholm; 2016. https://ecdc.europa.eu/sites/portal/files/documents/AER-HCAI-SSI.pdf. Accessed 21 Dec 2018.

  3. 3.

    Cassini A, Plachouras D, Eckmanns T, et al. Burden of six healthcare-associated infections on European population health: estimating incidence-based disability-adjusted life years through a population prevalence-based Modelling study. PLoS Med. 2016;13(10):1–16. https://doi.org/10.1371/journal.pmed.1002150.

    Article  Google Scholar 

  4. 4.

    Astagneau P, Rioux C, Golliot F, Brücker G. Morbidity and mortality associated with surgical site infections: results from the 1997-1999 INCISO surveillance. J Hosp Infect. 2001;48(4):267–74. https://doi.org/10.1053/jhin.2001.1003.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Bratzler DW. Use of antimicrobial prophylaxis for major surgery. Arch Surg. 2005;140(2):174. https://doi.org/10.1001/archsurg.140.2.174.

    Article  PubMed  Google Scholar 

  6. 6.

    Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello P. Adverse impact of surgical site infections in English hospitals. J Hosp Infect. 2005;60(2):93–103. https://doi.org/10.1016/j.jhin.2004.10.019.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Shaw E, Gomila A, Piriz M, et al. Multistate modelling to estimate excess length of stay and risk of death associated with organ/space infection after elective colorectal surgery. J Hosp Infect. 2018;100(4):400–5. https://doi.org/10.1016/j.jhin.2018.08.010.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Smith RL, Bohl JK, McElearney ST, et al. Wound infection after elective colorectal resection. Ann Surg. 2004;239(5):599-605-607. https://doi.org/10.1097/01.sla.0000124292.21605.99.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Leaper DJ, van Goor H, Reilly J, et al. Surgical site infection - a European perspective of incidence and economic burden. Int Wound J. 2004;1(4):247–73. https://doi.org/10.1111/j.1742-4801.2004.00067.x.

    Article  PubMed  Google Scholar 

  10. 10.

    Graf K, Ott E, Vonberg RP, et al. Surgical site infections-economic consequences for the health care system. Langenbeck's Arch Surg. 2011;396(4):453–9. https://doi.org/10.1007/s00423-011-0772-0.

    Article  Google Scholar 

  11. 11.

    Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect. 2017;96(1):1–15. https://doi.org/10.1016/j.jhin.2017.03.004.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Nichols R, Broido P, Condon R, Gorbach S, Nythus L. Effect of preoperative neomycin-erythromycin intestinal preparation on the incidence of infectious complications following colon surgery. Ann Surg. 1973;178(4):453–9.

    CAS  Article  Google Scholar 

  13. 13.

    Güenaga K, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery ( review ). Cochrane Database Syst Rev. 2011;9:CD001544. https://doi.org/10.1002/14651858.CD001544.pub4.www.cochranelibrary.com.

    Article  Google Scholar 

  14. 14.

    Slim K, Martin G. Mechanical bowel preparation before colorectal surgery. Where do we stand? J Visc Surg. 2015;153(2):85–7. https://doi.org/10.1016/j.jviscsurg.2015.10.004.

    Article  PubMed  Google Scholar 

  15. 15.

    Mulder T, Kluytmans-van den Bergh MFQ, de Smet AMGA, et al. Prevention of severe infectious complications after colorectal surgery using preoperative orally administered antibiotic prophylaxis (PreCaution): study protocol for a randomized controlled trial. Trials. 2018;19(1):51. https://doi.org/10.1186/s13063-018-2439-4.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Bauer MP, van de Garde EMW, van Kasteren MEE, Prins J, Vos M. SWAB Richtlijn Peri-Operatieve Profylaxe. 2017.

  17. 17.

    Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;20(5):271–4. https://doi.org/10.1086/646436.

    CAS  Article  Google Scholar 

  18. 18.

    EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters European Committee on Antimicrobial Susceptibility Testing Breakpoint Tables for Interpretation of MICs and Zone Diameters. 2020. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf. Accessed 13 Jan 2020.

  19. 19.

    ZZee KI van der, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36, een handleiding. Tweede herziene druk. UMCG / Rijksuniversiteit Groningen, Research Institute SHARE. 2012.

  20. 20.

    EMA. Guideline for Good Clinical Practice E6(R2). 2016.

    Google Scholar 

  21. 21.

    Mulder T, Crolla RMPH, Kluytmans-van den Bergh MFQ, et al. Preoperative oral antibiotic prophylaxis reduces surgical site infections after elective colorectal surgery: results from a before-after study. Clin Infect Dis 2018:0–2. doi:https://doi.org/10.1093/cid/ciy839.

  22. 22.

    PREZIES Referentiecijfers 2014-2018: Postoperatieve Wondinfecties. Tabel 7 50e En 75e Percentiel van de Operatieduur per Ingreep; 2014.

  23. 23.

    Bellows CF, Mills KT, Kelly TN, Gagliardi G. Combination of oral non-absorbable and intravenous antibiotics versus intravenous antibiotics alone in the prevention of surgical site infections after colorectal surgery: a meta-analysis of randomized controlled trials. Tech Coloproctol. 2011;15(4):385–95. https://doi.org/10.1007/s10151-011-0714-4.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev. 2014;5(5):CD001181. https://doi.org/10.1002/14651858.CD001181.pub4.

    Article  Google Scholar 

  25. 25.

    Cannon J, Altom L, Deierhoi R, et al. Oral antibiotics with mechanical bowel preparation reduce infection after elective colorectal resections. Dis Colon Rectum. 2012;55(5):e124 http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L71634787.

    Google Scholar 

  26. 26.

    Kaslow SR, Gani F, Alshaikh HN, Canner JK. Clinical outcomes following mechanical plus oral antibiotic bowel preparation versus oral antibiotics alone in patients undergoing colorectal surgery. BJS Open. 2018;2(4):238–45. https://doi.org/10.1002/bjs5.66.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Garfinkle R, Abou-Khalil J, Morin N, et al. Is there a role for Oral antibiotic preparation alone before colorectal surgery? ACS-NSQIP analysis by coarsened exact matching. Dis Colon Rectum. 2017;60(7):729–37. https://doi.org/10.1097/DCR.0000000000000851.

    Article  PubMed  Google Scholar 

  28. 28.

    Koller SE, Bauer ÃKW, Egleston BL, et al. Comparative Effectiveness and Risks of Bowel Preparation Before Elective Colorectal Surgery. 2018;267(4). https://doi.org/10.1097/SLA.0000000000002159.

  29. 29.

    Moghadamyeghaneh Z, Hanna MH, Carmichael JC, et al. Nationwide analysis of outcomes of bowel preparation in colon surgery. J Am Coll Surg. 2015;220(5):912–20. https://doi.org/10.1016/j.jamcollsurg.2015.02.008.

    Article  PubMed  Google Scholar 

  30. 30.

    Ohman KA, Wan L, Guthrie T, et al. Combination of Oral antibiotics and mechanical bowel preparation reduces surgical site infection in colorectal surgery. J Am Coll Surg. 2017;225(4):465–71. https://doi.org/10.1016/j.jamcollsurg.2017.06.011.

    Article  PubMed  Google Scholar 

  31. 31.

    Toh JWT, Phan K, Ctercteko G, et al. The role of mechanical bowel preparation and oral antibiotics for left-sided laparoscopic and open elective restorative colorectal surgery with and without faecal diversion. Int J Colorectal Dis. 2018;33(12):1781-1791. https://doi.org/10.1007/s00384-018-3166-8. Epub 2018 Sep 20.

  32. 32.

    Scarborough JE, Mantyh CR, Sun Z, Migaly J. Combined mechanical and Oral antibiotic bowel preparation reduces incisional surgical site infection and anastomotic leak rates after elective colorectal resection. Ann Surg. 2015;262(2):331–7. https://doi.org/10.1097/SLA.0000000000001041.

    Article  PubMed  Google Scholar 

  33. 33.

    Atkinson SJ, Swenson BR, Hanseman DJ, et al. In the absence of a mechanical bowel prep, does the addition of pre-operative Oral antibiotics to parental antibiotics decrease the incidence of surgical site infection after elective segmental colectomy? Surg Infect. 2015;16(6):728–32. https://doi.org/10.1089/sur.2014.215.

    Article  Google Scholar 

  34. 34.

    Shwaartz C, Fields AC, Sobrero M, Divino CM. Does bowel preparation for inflammatory bowel disease surgery matter? Color Dis. 2017;19(9):832–9. https://doi.org/10.1111/codi.13693.

    CAS  Article  Google Scholar 

  35. 35.

    Dolejs SC, Guzman MJ, Fajardo AD, et al. Bowel preparation is associated with reduced morbidity in elderly patients undergoing elective colectomy. J Gastrointest Surg. 2017;21(2):372–9. https://doi.org/10.1007/s11605-016-3314-9.

    Article  PubMed  Google Scholar 

  36. 36.

    Midura EF, Jung AD, Hanseman DJ, et al. Combination oral and mechanical bowel preparations decreases complications in both right and left colectomy. Surgery. 2018;163(3):528–34. https://doi.org/10.1016/j.surg.2017.10.023.

    Article  PubMed  Google Scholar 

  37. 37.

    Wittekamp BHJ, Oostdijk EAN, Marie A, De Smet GA, Bonten MJM. Colistin and tobramycin resistance during long- term use of selective decontamination strategies in the intensive care unit : a post hoc analysis. Crit Care. 2015;19(113):1–6. https://doi.org/10.1186/s13054-015-0838-4.

    Article  Google Scholar 

  38. 38.

    Oostdijk EAN, Smits L, de Smet AMGA, Leverstein-van Hall MA, Kesecioglu J, Bonten MJM. Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med. 2013;39(4):653–60. https://doi.org/10.1007/s00134-012-2761-3.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Houben AJM, Oostdijk EAN, van der Voort PHJ, et al. Selective decontamination of the oropharynx and the digestive tract, and antimicrobial resistance: a 4 year ecological study in 38 intensive care units in the Netherlands. J Antimicrob Chemother. 2014;69(3):797–804. https://doi.org/10.1093/jac/dkt416.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    Daneman N, Sarwar S, Fowler RA, Cuthbertson BH. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(4):328–41. https://doi.org/10.1016/S1473-3099(12)70322-5.

    Article  PubMed  Google Scholar 

  41. 41.

    Kluytmans-van den Bergh MFQ, Verhulst C, Willemsen LE, Verkade E, Bonten MJM, Kluytmans JAJW. Rectal carriage of extended-Spectrum-Beta-lactamase-producing Enterobacteriaceae in hospitalized patients: selective Preenrichment increases yield of screening. J Clin Microbiol. 2015;53(8):2709–12. https://doi.org/10.1128/JCM.01251-15.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317(3):3–16. https://doi.org/10.1056/NEJM198707163170304.

    Article  Google Scholar 

Download references

Acknowledgments

The PreCaution trial study group consisted of the following experts and investigators:

Coordinating study team: UMC Utrecht: JAJW Kluytmans (Principal investigator), T Mulder, MFQ Kluytmans-van den Bergh, F Kloosterman, MJM Bonten, S Nikolakopoulos; Amphia Hospital: NE van ‘t Veer. Project advisors: Amphia Hospital: RMPH Crolla, GP van der Schelling; Clinical centers and local investigators: Admiraal de Ruyter Hospital: RJ de Vos tot Nederveen Cappel, J Veenemans; Erasmus Medical Center: ARM Brandt, M Vos; Meander Medical Center: PM Verheijen, AJL Weersink; Reinier de Graaf Gasthuis: D Roos, E van der Vorm; Sint Antonius Hospital: A Smits, B Vlaminckx; University Medical Center Groningen: E Bathoorn, B van Etten, AMGA de Smet. Data safety and monitoring board: RA Coutinho, EGJM Pierik, H Wertheim, MCJ Bootsma. Independent expert: MB Ekkelenkamp.

We thank Stichting Apotheek Haarlemse Ziekenhuizen for the development and preparation of the study medication and Microvida Laboratory for Medical Microbiology (location Amphia Hospital) for the processing and analysis of rectal swabs.

Funding

The PreCaution trial was funded by Netherlands Organization for Health Research and Development (ZonMw, project number 522002011).

Author information

Affiliations

Authors

Contributions

TM was a member of the coordinating study team and led the writing of the protocol and manuscript, coordinated the submission of the protocol to the Medical Ethics Committee and coordinated manuscript submission. MK was a member of the coordinating study team and provided input into the design of the study, to the writing of the protocol, coordinated the microbiological analysis and contributed to the writing of the manuscript. BV was a local investigator and provided input into the manuscript. DR was a local investigator and provided input into the protocol and the manuscript. AMdS was a local investigator and provided input into the design of the study, the writing of the protocol and the manuscript. RV was a local investigator and provided input into the manuscript. PV was a local investigator and provided input into the manuscript. AB was a local investigator and provided input into the manuscript. AS was a local investigator and provided input into the manuscript. EvdV was a local investigator and provided input into the manuscript. BvE was a local investigator and provided input into manuscript. JV was a local investigator and provided input into the manuscript. AW was a local investigator and provided input into the manuscript. MV was a local investigator and provided input into the manuscript. NvtV was the coordinating trial pharmacist and provided input into the protocol. SN provided statistical input to the protocol and is the statistician on the trial. MB was a member of the coordinating study team and contributed to the design of the study and provided input into the protocol and the manuscript. JK was a member of the coordinating study team and as principal investigator of the trial, contributed to the design of the study and was a contributor to the protocol and to the writing of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jan Kluytmans.

Ethics declarations

Ethics approval and consent to participate

The Medical Ethics Committee of the UMC Utrecht (Utrecht, The Netherlands) has reviewed and approved the study (METC number 16/374). This trial was conducted in agreement with the declaration of Helsinki (Version 10, Fortaleza, October 2013), in accordance with the Medical Research Involving Human Subjects Act (WMO) and with the GCP guidelines issued by the European Union. The PreCaution trial is registered in the Netherlands Trial Register under NL5932 (previously: NTR6113) as well as in the EudraCT register under 2015–005736-17.

Consent for publication

All participants gave written informed consent for publication of the obtained data.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mulder, T., Kluytmans-van den Bergh, M., Vlaminckx, B. et al. Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: results of a multicenter randomized placebo-controlled clinical trial. Antimicrob Resist Infect Control 9, 84 (2020). https://doi.org/10.1186/s13756-020-00745-2

Download citation

Keywords

  • Infection control
  • Preoperative oral antibiotic prophylaxis
  • Colorectal surgery
  • Surgical site infection